Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

56.22 -2.28 (-3.90%)
Official Closing Price Updated: 7:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
66 67 Next >
3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street
None of these stocks have outperformed Nvidia so far this year. But the next 12 months could be a different story. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
These three healthcare stocks to sell are waving red flags at investors who should pay attention or suffer the consequences. 
Via InvestorPlace
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
Via Talk Markets
Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study
Bristol Myers Squibb & Co (NYSE: BMY) announced interim data from Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant (before surgery) Opdivo (nivolumab) with chemotherapy... 
Via Benzinga
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and... 
Via Benzinga
Exposures Product Safety
Looking Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Undervalued Dividend Stocks to Buy Now
These two pharma titans are proven income vehicles. 
Via The Motley Fool
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now. 
Via InvestorPlace
Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth
Bristol-Myers Squibb & Co (NYSE: BMY) announced its ambitious plan to double the number of treatments undergoing clinical trials in the next 18 months, focusing primarily on targeted protein  
Via Benzinga
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
From Bristol Myers Squibb
Via Business Wire
The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.
Roz Brewer stepped down from leading Walgreens, and the next CEO is a tough choice. These three make the cut. 
Via InvestorPlace
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a p 
Via Benzinga
Bristol Myers Squibb's Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients
Bristol Myers Squibb & Co (NYSE: BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo... 
Via Benzinga
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug
This story was first published on the Benzinga India portal. 
Via Benzinga
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
From Bristol Myers Squibb
Via Business Wire
The 3 Best Pharma Stocks to Buy Now: September 2023
There are pharma stocks to buy for each type of investor. This article explores the best options in the industry. 
Via InvestorPlace
Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug
Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
From Bristol Myers Squibb
Via Business Wire
How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low
President Joe Biden’s Inflation Reduction Act, which allows Medicare to negotiate the price of some prescription drugs, remains the talk of the town as investors sell off shares in pharmaceutical... 
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership
On Friday, Judge Thomas Rose, serving in the U.S. 
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in September
Income investors should really like these biopharma stocks with juicy dividends. 
Via The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
3 Undervalued Healthcare Stocks In 2023
These 3 undervalued healthcare stocks in 2023 are attractive today for their attractive valuations and total return potential. 
Via Talk Markets
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS